Characteristics of post-vaccination immunity in students vaccinated against hepatitis B in the first year of life

Author:

Shamsheva O. V.1ORCID,Kochetova E. O.1ORCID,Polesko I. V.1ORCID,Mayorova O. A.2ORCID,Belyakova V. V.2ORCID,Konev V. A.1ORCID

Affiliation:

1. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

2. O.K. Gavrilov Blood Center

Abstract

Most researchers agree that the level of protective anti-HBs decreases with age after 3-fold immunization in the first year of life, which requires the introduction of a booster dose at least 5—7 years after the completed vaccination. It is necessary to continue monitoring those vaccinated against hepatitis B in the first year of life, including those from occupational risk groups.Objective: to assess the frequency and level of anti-HBs 18 or more years after the completed course of vaccination against hepatitis B according to the standard scheme in the first year of life and to identify risk groups that need revaccination.Of 116 donor students in Moscow, 18—22 years after the completed course of vaccination against hepatitis B according to the standard scheme carried out in the first year of life, in 42.3% of cases, the titer of specific antibodies was determined below the protective level (< 10 mME/ml). At the same time, the share of seronegative individuals among medical students was higher (52.8%). Of 116 donor students, in 38.8% of cases, the titer of protective antibodies was determined in low (10—100 mME/ml) and only in 13.8% — in high (100—1000 mME/ml) and in 5.2% — very high (> 1000 mME/ml) values. Markers of DNA HBV, HBsAg, and anti-HBcor were not detected in any cases. Medical students primarily need a revaccination against hepatitis B without a preliminary study of the initial titers of specific antibodies.

Publisher

Journal of Childrens Infections

Subject

General Medicine

Reference10 articles.

1. Информационный бюллетень ВОЗ. Гепатит В. https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-b [Дата обращения 19.07.2021]

2. Information on infectious and parasitic diseases for January-December 2018 in the Russian Federation. Detskie Infektsii=Children's Infections, 2019; 18(1):5. (In Russ.) https://doi.org/10.22627/2072-8107-2019-18-1

3. Pierre Van Damme. Persistence of HBsAg Hepatitis B vaccines. WHO position paper. J Viral Hepat., Jule 2017/7 JULY 2017. 92th YEAR/No 27, 2017; 92:369—392.

4. Grazhdantseva A.A. et al. Study of immunity indicators during vaccination against hepatitis B. Epidemiology and Vaccine Prevention. 2008; 5 (42). (In Russ.)

5. Shilova I.V., L.G. Goryacheva, S.M. Harit, A.S. Drap. Evaluation of the long-term effectiveness of immunization against hepatitis B within the National Vaccination Calendar. Detskie Infektsii=Children's Infections. 2017; 16(4):49—51. (In Russ.) https://doi.org/10.22627/2072-8107-2017-16-4-49-51

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3